

Radiological findings :.....

Details of previous biopsy or cytology report :.....

Immunohistochemistry study report:.....

ER, PR, Her2 neu status:.....

Drug Details: (PDL-1 IHC indicated in patients with specific tumor type in order to predict their responses to treatment with PDL-1 inhibitors. The specific PDL-1 clone scoring method and eligibility requirements are dependant on the tumor type, stage of malignancy, previous treatment outcomes and specific PDL-1 inhibitors being considered)

Tick	Clone	Drug
<input type="checkbox"/>	Sp263	Nivolumab (opdivo)
<input type="checkbox"/>	Sp263	Durvalumab (imfinzi)
<input type="checkbox"/>	Sp142	Atezolilumab (Tecentriq)
<input type="checkbox"/>	Sp142	Atezolilumab (Tecentriq)
<input type="checkbox"/>	Sp142	Atezolilumab (Tecentriq) Plus nab- paclitaxel (Abaxane)
<input type="checkbox"/>	22C3	Pembrolizumab

Signature and Contact Number of (Requester):